Research programme: beta-2 adrenergic receptor agonists - Pfizer

Drug Profile

Research programme: beta-2 adrenergic receptor agonists - Pfizer

Alternative Names: Compound X; UK 503590

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in United Kingdom (Inhalation, Inhalant)
  • 08 Oct 2008 Final pharmacodynamics data from a preclinical trial in Asthma presented at the 18th Annual Congress of the European Respiratory Society (ERS-2008)
  • 21 May 2008 Preclinical trials in Asthma in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top